Summary
- Previous Close
- $47.98
- Open
- $47.98
- Day's Range
- $47.98 – $47.98
- 52 Week Range
- $11.56 – $48.27
- Volume
- 783,730
- Avg. Volume
- 925,778
- Market Cap
- $1.23B
- Beta (5Y Monthly)
- 1.58
- PE Ratio (TTM)
- --
- EPS (TTM)
- -$2.89
- Earnings Date
- --
- Forward Dividend & Yield
- --
- Ex-Dividend Date
- Oct 20, 2023
- 1y Target Est
- $48.50
Profile: Tourmaline Bio, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Full-time employees
- 74
- CEO
- Sandeep C. Kulkarni
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.